{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:15:17Z","timestamp":1779110117361,"version":"3.51.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2020-1782"],"award-info":[{"award-number":["2020-1782"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2021-0159"],"award-info":[{"award-number":["2021-0159"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2020-SERIEA-02037"],"award-info":[{"award-number":["PICT-2020-SERIEA-02037"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012478","name":"Secretaria de Ciencia y Tecnolog\u00eda - Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["PIDTA-2024"],"award-info":[{"award-number":["PIDTA-2024"]}],"id":[{"id":"10.13039\/100012478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012478","name":"Secretaria de Ciencia y Tecnolog\u00eda - Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["33820230100458CB"],"award-info":[{"award-number":["33820230100458CB"]}],"id":[{"id":"10.13039\/100012478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012478","name":"Secretaria de Ciencia y Tecnolog\u00eda - Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["33620230100035CB"],"award-info":[{"award-number":["33620230100035CB"]}],"id":[{"id":"10.13039\/100012478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["2021-2023"],"award-info":[{"award-number":["2021-2023"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["28720210101293CO"],"award-info":[{"award-number":["28720210101293CO"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13346-025-01989-4","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:26:45Z","timestamp":1760387205000},"page":"1877-1893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering a nifurtimox nanosuspension: toward improved pharmaceutical attributes"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8482-4144","authenticated-orcid":false,"given":"Mar\u00eda Sol","family":"Magi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-2028","authenticated-orcid":false,"given":"Luc\u00eda","family":"Lopez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1943-4891","authenticated-orcid":false,"given":"M\u00f3nica Cristina","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-9087","authenticated-orcid":false,"given":"Santiago Daniel","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-7983","authenticated-orcid":false,"given":"Alvaro Federico","family":"Jimenez-Kairuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"publisher","unstructured":"Andrade MV, Noronha KVM, de Souza S, de A, Motta-Santos AS, Braga PEF, Bracarense H, et al. The economic burden of Chagas disease: A systematic review. PLoS Negl Trop Dis. 2023;17(11). https:\/\/doi.org\/10.1371\/journal.pntd.0011757","DOI":"10.1371\/journal.pntd.0011757"},{"key":"1989_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.actatropica.2016.01.002","volume":"156","author":"EE Conners","year":"2016","unstructured":"Conners EE, Vinetz JM, Weeks JR, Brouwer KC. A global systematic review of Chagas disease prevalence among migrants. Acta Trop. 2016;156:68\u201378. https:\/\/doi.org\/10.1016\/j.actatropica.2016.01.002","journal-title":"Acta Trop"},{"issue":"5","key":"1989_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","volume":"97","author":"P Sales Junior","year":"2017","unstructured":"Sales Junior P, Molina I, Fonseca Murta SM, et al. Experimental and clinical treatment of Chagas disease: A review. Am J Trop Med Hyg. 2017;97(5):1289\u2013303. https:\/\/doi.org\/10.4269\/ajtmh.16-0761","journal-title":"Am J Trop Med Hyg"},{"key":"1989_CR4","doi-asserted-by":"publisher","unstructured":"Cucunub\u00e1 ZM, Guti\u00e9rrez-Romero SA, Ram\u00edrez JD, Vel\u00e1squez-Ortiz N, Ceccarelli S, Parra-Henao G, et al. The epidemiology of Chagas disease in the Americas. Lancet Reg Health. 2024;37. https:\/\/doi.org\/10.1016\/j.lana.2024.100881","DOI":"10.1016\/j.lana.2024.100881"},{"issue":"11","key":"1989_CR5","doi-asserted-by":"publisher","first-page":"e0010376","DOI":"10.1371\/journal.pntd.0010376","volume":"16","author":"S Matthews","year":"2022","unstructured":"Matthews S, Tannis A, Puchner KP, Bottazzi ME, Cafferata ML, Comande\u00b4 D, et al. Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022;16(11):e0010376. https:\/\/doi.org\/10.1371\/journal.pntd.0010376","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1989_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1590\/0074-02760140405","volume":"110","author":"Y Carlier","year":"2015","unstructured":"Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P. Congenital Chagas disease: an update. Mem Inst Oswaldo Cruz. 2015;110(3):363\u20138. https:\/\/doi.org\/10.1590\/0074-02760140405","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"1989_CR7","doi-asserted-by":"publisher","unstructured":"Sereno D, Oury B, Grijalva MJ. Chagas disease across the ages: A historical view and commentary on navigating future challenges. Microorganisms. 2024;12(6). https:\/\/doi.org\/10.3390\/microorganisms12061153","DOI":"10.3390\/microorganisms12061153"},{"key":"1989_CR8","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-v\u00e9lez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). Tenth Edit. Hunter\u2019s Tropical Medicine and Emerging Infectious Disease. 2020:762\u2013775. Available from: https:\/\/doi.org\/10.1016\/B978-0-323-55512-8.00103-4","DOI":"10.1016\/B978-0-323-55512-8.00103-4"},{"issue":"9","key":"1989_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eimc.2020.04.0","volume":"39","author":"JA P\u00e9rez-Molina","year":"2021","unstructured":"P\u00e9rez-Molina JA, Crespillo-And\u00fajar C, Bosch-Nicolau P, Molina I. Trypanocidal treatment of Chagas disease. Enfermedades Infecciosas Y microbiolog\u00eda cl\u00ednica. 2021;39(9):458\u201370. https:\/\/doi.org\/10.1016\/j.eimc.2020.04.0","journal-title":"Enfermedades Infecciosas Y microbiolog\u00eda cl\u00ednica"},{"key":"1989_CR10","doi-asserted-by":"publisher","first-page":"105080","DOI":"10.1016\/j.actatropica.2019.105080","volume":"198","author":"EC Arr\u00faa","year":"2019","unstructured":"Arr\u00faa EC, Seremeta KP, Bedogni GR, Okulik NB, Salomon CJ. Nanocarriers for effective delivery of benznidazole and Nifurtimox in the treatment of Chagas disease: A review. Acta Trop. 2019;198:105080. https:\/\/doi.org\/10.1016\/j.actatropica.2019.105080","journal-title":"Acta Trop"},{"key":"1989_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1590\/S0074-02762007005000106","volume":"102","author":"J Jannin","year":"2007","unstructured":"Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz Rio De Janeiro. 2007;102:95\u20137.","journal-title":"Mem Inst Oswaldo Cruz Rio De Janeiro"},{"key":"1989_CR12","unstructured":"World Health Organization. WHO model list of essential medicines \u2013 22nd list. 2021. Geneva: World Health Organization; 2021. (WHO\/MHP\/HPS\/EML\/2021.01). Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/345533\/WHO-MHP-HPS-EML-2021.01-eng.pdf"},{"key":"1989_CR13","unstructured":"World Health Organization. WHO model list of essential medicines for children \u2013 8th list. 2021. Geneva: World Health Organization; 2021. (WHO\/MHP\/HPS\/EML\/2021.03). Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/345534\/WHO-MHP-HPS-EML-2021.03-eng.pdf"},{"key":"1989_CR14","unstructured":"U.S. Food and Drug Administration. Drug Trials Snapshots: Lampit. Silver Spring (MD): FDA. 2020 Aug 6. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-trials-snapshots-lampit"},{"key":"1989_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.xphs.2023.02.015","volume":"112","author":"AB Moroni","year":"2023","unstructured":"Moroni AB, Calvo NL, Kaufman TS. Selected aspects of the analytical and pharmaceutical profiles of Nifurtimox. J Pharm Sci. 2023;112:1523\u201338. https:\/\/doi.org\/10.1016\/j.xphs.2023.02.015","journal-title":"J Pharm Sci"},{"key":"1989_CR16","doi-asserted-by":"publisher","unstructured":"Stass H, Just S, Weimann B, Ince I, Willmann S, Feleder E, et al. Clinical investigation of the biopharmaceutical characteristics of Nifurtimox tablets \u2013 Implications for quality control and application. Eur J Pharm Sci. 2021;166. https:\/\/doi.org\/10.1016\/j.ejps.2021.105940","DOI":"10.1016\/j.ejps.2021.105940"},{"issue":"5","key":"1989_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/cpdd.871","volume":"10","author":"H Stass","year":"2021","unstructured":"Stass H, Feleder E, Garcia-Bournissen F, Nagelschmitz J, Weimann B, Yerino G, et al. Biopharmaceutical characteristics of Nifurtimox tablets for Age- and body Weight-Adjusted dosing in patients with Chagas disease. Clin Pharmacol Drug Dev. 2021;10(5):542\u201355. https:\/\/doi.org\/10.1002\/cpdd.871","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1989_CR18","doi-asserted-by":"publisher","unstructured":"Bedogni GR, Lima AL, Gross IP, Menezes TP, Talvani A, Cunha-Filho M et al. 3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti-Trypanosoma cruzi Studies. Pharmaceutics. 2025;17(1). https:\/\/doi.org\/10.3390\/pharmaceutics17010080","DOI":"10.3390\/pharmaceutics17010080"},{"issue":"6","key":"1989_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4269\/ajtmh.15-0256","volume":"93","author":"MJ Olivera","year":"2015","unstructured":"Olivera MJ, Cucunub\u00e1 ZM, \u00c1lvarez CA, Nicholls RS. Safety profile of Nifurtimox and treatment interruption for chronic Chagas disease in Colombian adults. Am J Trop Med Hyg. 2015;93(6):1224\u201330.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"1989_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.actatropica.2013.04.003","volume":"127","author":"JA P\u00e9rez-Molina","year":"2013","unstructured":"P\u00e9rez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, D\u00edaz-Men\u00e9ndez M, Albajar-Vi\u00f1as P, et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 2013;127(2):101\u20134. https:\/\/doi.org\/10.1016\/j.actatropica.2013.04.003","journal-title":"Acta Trop"},{"issue":"12","key":"1989_CR21","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.cmi.2018.06.006","volume":"24","author":"C Crespillo-And\u00fajar","year":"2018","unstructured":"Crespillo-And\u00fajar C, Chamorro-Tojeiro S, Norman F, Monge-Maillo B, L\u00f3pez-V\u00e9lez R, P\u00e9rez-Molina JA. Toxicity of Nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. Clin Microbiol Infect. 2018;24(12):1344.e1-1344.e4. https:\/\/doi.org\/10.1016\/j.cmi.2018.06.006","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"1989_CR22","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1086\/656917","volume":"51","author":"Y Jackson","year":"2010","unstructured":"Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of Nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51(10):e69\u201375. https:\/\/doi.org\/10.1086\/656917","journal-title":"Clin Infect Dis"},{"key":"1989_CR23","doi-asserted-by":"publisher","first-page":"e210034","DOI":"10.1590\/0074-02760210034","volume":"117","author":"F Mendes","year":"2022","unstructured":"Mendes F, de SNS, Perez-Molina JA, Angheben A, Meymandi SK, Sosa-Estani S, Molina I. Critical analysis of Chagas disease treatment in different countries. Mem Inst Oswaldo Cruz. 2022;117:e210034. https:\/\/doi.org\/10.1590\/0074-02760210034","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"1989_CR24","doi-asserted-by":"publisher","unstructured":"Mazzeti AL, Gon\u00e7alves KR, Boasquivis PF, Bahia MT, Mosqueira VCF. Development and characterization of innovative Nifurtimox formulations as therapeutic alternative for Chagas disease. Trop Med Infect Dis. 2025;10(50). https:\/\/doi.org\/10.3390\/tropicalmed10020050","DOI":"10.3390\/tropicalmed10020050"},{"issue":"10","key":"1989_CR25","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/bcp.13650","volume":"84","author":"JM del Moral Sanchez","year":"2018","unstructured":"del Moral Sanchez JM, Gonzalez-Alvarez I, Cerda-Revert A, Gonzalez-Alvarez M, Navarro-Ruiz A, Amidon GL, et al. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. Br J Clin Pharmacol. 2018;84(10):2231\u201341. https:\/\/doi.org\/10.1111\/bcp.13650","journal-title":"Br J Clin Pharmacol"},{"key":"1989_CR26","unstructured":"The International Pharmacopeia 10th Ed. Nifurtimox (Nifurtimoxum) monograph, WHO: Geneva, Switzerland, 2020."},{"key":"1989_CR27","doi-asserted-by":"publisher","unstructured":"Bedogni G, Arr\u00faa E, Seremeta K, Okulik N, Salomon C. Elucidating the complexation of Nifurtimox with cyclodextrins. J Mol Liq. 2023;382. https:\/\/doi.org\/10.1016\/j.molliq.2023.121852","DOI":"10.1016\/j.molliq.2023.121852"},{"key":"1989_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejpb.2023.01.008","volume":"184","author":"AB Moroni","year":"2023","unstructured":"Moroni AB, Mayoral EP, Lionello DF, Vega DR, Kaufman TS, Calvo NL. Solid-state properties of Nifurtimox. Preparation, analytical characterization, and stability of an amorphous phase. Eur J Pharm Biopharm. 2023;184:25\u201335. https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.008","journal-title":"Eur J Pharm Biopharm"},{"key":"1989_CR29","doi-asserted-by":"publisher","unstructured":"Gross IP, Lima AL, Bedogni GR, Sa-Barreto L, Gratieri T, Gelfuso GM, et al. Melt crystallization and thermal degradation profile of the antichagasic drug Nifurtimox. J Pharm Biomed Anal. 2024;239. https:\/\/doi.org\/10.1016\/j.jpba.2023.115878","DOI":"10.1016\/j.jpba.2023.115878"},{"issue":"3","key":"1989_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jconrel.2012.03.013","volume":"160","author":"L Gao","year":"2012","unstructured":"Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Controlled Release. 2012;160(3):418\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.013","journal-title":"J Controlled Release"},{"key":"1989_CR31","doi-asserted-by":"publisher","first-page":"101607","DOI":"10.1016\/j.jddst.2020.101607","volume":"56","author":"J Liu","year":"2020","unstructured":"Liu J, Tu L, Cheng M, Feng J, Jin Y. Mechanisms for oral absorption enhancement of drugs by nanocrystals. J Drug Deliv Sci Technol. 2020;56:101607. https:\/\/doi.org\/10.1016\/j.jddst.2020.101607","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"1989_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.drudis.2018.01.016","volume":"23","author":"M Malamatari","year":"2018","unstructured":"Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23(3):534\u201347. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.016","journal-title":"Drug Discov Today"},{"key":"1989_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jconrel.2022.03.012","volume":"345","author":"MB McGuckin","year":"2022","unstructured":"McGuckin MB, Wang J, Ghanma R, Qin N, Palma SD, Donnelly RF, et al. Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. J Controlled Release. 2022;345:334\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.012","journal-title":"J Controlled Release"},{"key":"1989_CR34","doi-asserted-by":"publisher","first-page":"125063","DOI":"10.1016\/J.IJPHARM.2024.125063","volume":"669","author":"L Lopez-Vidal","year":"2025","unstructured":"Lopez-Vidal L, Tinti M, Melian ME, Canton L, Lorenzutti M, Schofs L, et al. In vivo Pharmacokinetic study and PBPK modeling: comparison between 3D-printed nanocrystals and solid dispersions. Int J Pharm. 2025;669:125063. https:\/\/doi.org\/10.1016\/J.IJPHARM.2024.125063","journal-title":"Int J Pharm"},{"key":"1989_CR35","doi-asserted-by":"publisher","unstructured":"Lopez-Vidal L, Real DA, Paredes AJ, Real JP, Palma SD. 3D-Printed nanocrystals for oral administration of the drugs. Drug Delivery Using Nanomaterials. 2022;109\u201333. https:\/\/doi.org\/10.1201\/9781003168584-5","DOI":"10.1201\/9781003168584-5"},{"key":"1989_CR36","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/j.2042-7158.2010.01022.x","volume":"62","author":"L Peltonen","year":"2010","unstructured":"Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62:62:1569\u201379. https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01022.x","journal-title":"J Pharm Pharmacol"},{"key":"1989_CR37","doi-asserted-by":"publisher","unstructured":"Catlin EJ, Lopez-Vidal Luc\u00eda, Donnelly RF, Alejandro J. Paredes. A dynamic duo comes of age: nanocrystals and microneedles for hydrophobic drug delivery. Expert Opin Drug Delivery. 2025;1\u201318. https:\/\/doi.org\/10.1080\/17425247.2025.2531059","DOI":"10.1080\/17425247.2025.2531059"},{"key":"1989_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/20415990.2024.2380244","author":"MS Magi","year":"2024","unstructured":"Magi MS, Lopez-Vidal L, Garc\u00eda MC, Stempin CC, Marin C, Maletto B, et al. Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease. Ther Deliv. 2024. https:\/\/doi.org\/10.1080\/20415990.2024.2380244","journal-title":"Ther Deliv"},{"key":"1989_CR39","doi-asserted-by":"publisher","first-page":"119501","DOI":"10.1016\/j.ijpharm.2020.119501","volume":"585","author":"AJ Paredes","year":"2020","unstructured":"Paredes AJ, Camacho NM, Schofs L, Dib A, Zarazaga M, del Litterio P. Ricobendazole nanocrystals obtained by media milling and spray drying: Pharmacokinetic comparison with the micronized form of the drug. Int J Pharm. 2020;585:119501. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119501","journal-title":"Int J Pharm"},{"key":"1989_CR40","doi-asserted-by":"publisher","unstructured":"Formica ML, Awde Alfonso HG, Paredes AJ, Melian ME, Camacho NM, Faccio R, et al. Development of triamcinolone acetonide nanocrystals for ocular administration. Pharmaceutics. 2023;15(2). https:\/\/doi.org\/10.3390\/pharmaceutics15020683","DOI":"10.3390\/pharmaceutics15020683"},{"key":"1989_CR41","doi-asserted-by":"publisher","unstructured":"Lopez-Vidal L, Parodi P, Actis MR, Camacho N, Real DA, Paredes AJ, et al. Formulation and optimization of pH-sensitive nanocrystals for improved oral delivery. Drug Deliv Transl Res. 2023;13. https:\/\/doi.org\/10.1007\/s13346-023-01463-z","DOI":"10.1007\/s13346-023-01463-z"},{"key":"1989_CR42","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Molina JA, Molina I. Chagas disease. The Lancet. 2018;391:82\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(17)31612-4","DOI":"10.1016\/S0140-6736(17)31612-4"},{"issue":"1","key":"1989_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.2042-7158.1975.tb09378.x","volume":"27","author":"KA Khan","year":"1975","unstructured":"Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27(1):48\u20139. doi:10.1111\/J.2042- 7158.1975.TB09378.X.","journal-title":"J Pharm Pharmacol"},{"key":"1989_CR44","doi-asserted-by":"publisher","unstructured":"Fortes Francisco A, Jayawardhana S, Taylor MC, Lewis MD, Kelly JM. Assessing the effectiveness of curative benznidazole treatment in preventing chronic cardiac pathology in experimental models of Chagas disease. 2018; https:\/\/doi.org\/10.1128\/AAC","DOI":"10.1128\/AAC"},{"key":"1989_CR45","doi-asserted-by":"publisher","unstructured":"Garc\u00eda MC, Eberhardt N, Sanmarco LM, Ponce NE, Jimenez-Kairuz AF, Aoki MP. Improved efficacy and safety of low doses of benznidazole-loaded multiparticulate delivery systems in experimental Chagas disease therapy. Eur J Pharm Sci. 2021;164. https:\/\/doi.org\/10.1016\/j.ejps.2021.105912","DOI":"10.1016\/j.ejps.2021.105912"},{"key":"1989_CR46","doi-asserted-by":"publisher","unstructured":"Pr\u00e4bst K, Engelhardt H, Ringgeler S, H\u00fcbner H. Basic colorimetric proliferation assays: MTT, WST, and resazurin. Methods in molecular biology. Humana Press Inc.; 2017. pp. 1\u201317. https:\/\/doi.org\/10.1007\/978-1-4939-6960-9_1","DOI":"10.1007\/978-1-4939-6960-9_1"},{"issue":"6","key":"1989_CR47","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1128\/AAC.00404-16","volume":"60","author":"MC Garc\u00eda","year":"2016","unstructured":"Garc\u00eda MC, Ponce NE, Sanmarco LM, Manzo RH, Jimenez-Kairuz AF, Aoki MP. Clomipramine and benznidazole act synergistically and ameliorate the outcome of experimental Chagas disease. Antimicrob Agents Chemother. 2016;60(6):3700\u20138. https:\/\/doi.org\/10.1128\/AAC.00404-16","journal-title":"Antimicrob Agents Chemother"},{"key":"1989_CR48","doi-asserted-by":"crossref","unstructured":"Caldwell GW, Yan Z. Rapidly Distinguishing Reversible and Time-Dependent CYP450 Inhibition Using Human Liver Microsomes, Co-incubation, and Continuous Fluorometric Kinetic Analyses. In: Optimization in Drug Discovery: In Vitro Methods. Second Edi. 2014:281\u2013303. Available from: http:\/\/www.springer.com\/series\/7653","DOI":"10.1007\/978-1-62703-742-6_17"},{"key":"1989_CR49","unstructured":"Lakshmi P, Kumar GA. Nanosuspension technology: A review. Int J Pharm Pharm Sci. 2010;2(SUPPL. 4):35\u201340."},{"key":"1989_CR50","doi-asserted-by":"publisher","first-page":"121862","DOI":"10.1016\/j.ijpharm.2022.121862","volume":"623","author":"Y Tian","year":"2022","unstructured":"Tian Y, Wang S, Yu Y, Sun W, Fan R, Shi J, et al. Review of nanosuspension formulation and process analysis in wet media milling using microhydrodynamic model and emerging characterization methods. Int J Pharm. 2022;623:121862. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121862","journal-title":"Int J Pharm"},{"key":"1989_CR51","doi-asserted-by":"publisher","unstructured":"Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 2016;8(16). https:\/\/doi.org\/10.3390\/pharmaceutics8020016","DOI":"10.3390\/pharmaceutics8020016"},{"issue":"12","key":"1989_CR52","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","volume":"23","author":"G Dumortier","year":"2006","unstructured":"Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and Pharmacological characteristics. Pharm Res. 2006;23(12):2709\u201328. https:\/\/doi.org\/10.1007\/s11095-006-9104-4","journal-title":"Pharm Res"},{"key":"1989_CR53","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3109\/03639045.2016.1151036","volume":"42","author":"AJ Paredes","year":"2016","unstructured":"Paredes AJ, Llabot JM, S\u00e1nchez Bruni S, et al. Self-dispersible nanocrystals of albendazole produced by high pressure homogenization and spray-drying. Drug Dev Ind Pharm. 2016;42:1564\u201370.","journal-title":"Drug Dev Ind Pharm"},{"key":"1989_CR54","doi-asserted-by":"publisher","first-page":"121311","DOI":"10.1016\/j.ijpharm.2021.121311","volume":"611","author":"L Lopez-Vidal","year":"2022","unstructured":"Lopez-Vidal L, Real JP, Real DA, Camacho N, Kogan MJ, Paredes AJ, et al. Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs. Int J Pharm. 2022;611:121311. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121311","journal-title":"Int J Pharm"},{"key":"1989_CR55","doi-asserted-by":"publisher","unstructured":"Samimi S, Maghsoudnia N, Eftekhari RB, Dorkoosh F. Lipid-Based nanoparticles for drug delivery Systems. Characterization and biology of nanomaterials for drug delivery. 2019;47\u201376. https:\/\/doi.org\/10.1016\/B978-0-12-814031-4.00003-9","DOI":"10.1016\/B978-0-12-814031-4.00003-9"},{"key":"1989_CR56","doi-asserted-by":"publisher","unstructured":"N\u00e9meth Z, Cs\u00f3ka I, Semnani Jazani R, Sipos B, Haspel H, Kozma G, et al. Quality by Design-Driven zeta potential optimisation study of liposomes with charge imparting membrane additives. Pharmaceutics. 2022;14(9). https:\/\/doi.org\/10.3390\/pharmaceutics14091798","DOI":"10.3390\/pharmaceutics14091798"},{"key":"1989_CR57","doi-asserted-by":"publisher","first-page":"655435","DOI":"10.3389\/fmolb.2021.655435","volume":"8","author":"SD Choudhury","year":"2021","unstructured":"Choudhury SD. Nano-Medicines a hope for Chagas Disease! Front Mol Biosci. 2021;8:655435. https:\/\/doi.org\/10.3389\/fmolb.2021.655435","journal-title":"Front Mol Biosci"},{"issue":"6","key":"1989_CR58","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ajps.2018.08.010","volume":"13","author":"W Dong","year":"2018","unstructured":"Dong W, Su X, Xu M, Hu M, Sun Y, Zhang P. Preparation, characterization, and in vitro\/vivo evaluation of polymer-assisting formulation of Atorvastatin calcium based on solid dispersion technique. Asian J Pharm Sci. 2018;13(6):546\u201354. https:\/\/doi.org\/10.1016\/j.ajps.2018.08.010","journal-title":"Asian J Pharm Sci"},{"key":"1989_CR59","doi-asserted-by":"publisher","unstructured":"Csics\u00e1k D, Szoll\u00e1th R, K\u00e1d\u00e1r S, Ambrus R, Bartos C, Balogh E, et al. The effect of the particle size reduction on the biorelevant solubility and dissolution of poorly soluble drugs with different Acid-Base character. Pharmaceutics. 2023;15278. https:\/\/doi.org\/10.3390\/pharmaceutics15010278","DOI":"10.3390\/pharmaceutics15010278"},{"key":"1989_CR60","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.pscia.2023.100031","volume":"2","author":"ZH Mok","year":"2024","unstructured":"Mok ZH. The effect of particle size on drug bioavailability in various parts of the body. Pharm Sci Adv. 2024;2:100031. https:\/\/doi.org\/10.1016\/j.pscia.2023.100031","journal-title":"Pharm Sci Adv"},{"key":"1989_CR61","doi-asserted-by":"publisher","unstructured":"Gross IP, Lima AL, Bedogni GR, Sa-Barreto L, Gratieri T, Gelfuso GM, et al. Conformational analysis and spectroscopic properties of antichagasic Nifurtimox. Spectrochim Acta Mol Biomol Spectrosc. 2024;316. https:\/\/doi.org\/10.1016\/j.saa.2024.124346","DOI":"10.1016\/j.saa.2024.124346"},{"key":"1989_CR62","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1080\/07373937.2021.1983823","volume":"40","author":"J Chakraborty","year":"2022","unstructured":"Chakraborty J, Subash M, Thorat BN. Drying induced polymorphic transformation of pharmaceutical ingredients: a critical review of recent progresses and challenges. Drying Technol. 2022;40:2817\u201335. https:\/\/doi.org\/10.1080\/07373937.2021.1983823","journal-title":"Drying Technol"},{"key":"1989_CR63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/J.SUPFLU.2012.01.009","volume":"66","author":"J Kluge","year":"2012","unstructured":"Kluge J, Muhrer G, Mazzotti M. High pressure homogenization of pharmaceutical solids. J Supercrit Fluids. 2012;66:380\u20138. https:\/\/doi.org\/10.1016\/J.SUPFLU.2012.01.009","journal-title":"J Supercrit Fluids"},{"key":"1989_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.colsurfb.2019.01.039","volume":"177","author":"KP Seremeta","year":"2019","unstructured":"Seremeta KP, Arr\u00faa EC, Okulik NB, Salomon CJ. Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease? Colloids Surf B Biointerfaces. 2019;177:169\u201377. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.01.039","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"1989_CR65","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijpharm.2015.09.013","volume":"495","author":"M Malamatari","year":"2015","unstructured":"Malamatari M, Somavarapu S, Bloxham M, Buckton G. Nanoparticle agglomerates of indomethacin: the role of poloxamers and matrix former on their dissolution and aerosolisation efficiency. Int J Pharm. 2015;495(1):516\u201326. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.013","journal-title":"Int J Pharm"},{"key":"1989_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/sci1020048","volume":"1","author":"S Nanaki","year":"2019","unstructured":"Nanaki S, Eleftheriou RM, Barmpalexis P, Kostoglou M, Karavas E, Bikiaris D. Evaluation of dissolution enhancement of aprepitant drug in ternary pharmaceutical solid dispersions with Soluplus\u00ae and poloxamer 188 prepared by melt mixing. Sci. 2019;1:48. https:\/\/doi.org\/10.3390\/sci1020048","journal-title":"Sci"},{"key":"1989_CR67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fchem.2020.00212","volume":"8","author":"X Lin","year":"2020","unstructured":"Lin X, Shi Y, Yu SS, Li S, Li W, Li M, et al. Preparation of Poloxamer188-b-PCL and study on in vitro radioprotection activity of Curcumin-Loaded nanoparticles. Front Chem. 2020;8:212. https:\/\/doi.org\/10.3389\/fchem.2020.00212","journal-title":"Front Chem"},{"key":"1989_CR68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics12010053","volume":"12","author":"D Medarevi\u0107","year":"2020","unstructured":"Medarevi\u0107 D, Ibri\u0107 S, Vardaka E, Mitri\u0107 M, Nikolakakis I, Kachrimanis K. Insight into the formation of glimepiride nanocrystals by wet media milling. Pharmaceutics. 2020;12:53. https:\/\/doi.org\/10.3390\/pharmaceutics12010053","journal-title":"Pharmaceutics"},{"key":"1989_CR69","doi-asserted-by":"publisher","unstructured":"Magi MS, Lopez-Vidal L, Rega P, Ibarra M, Palma SD, Jimenez Kairuz A, et al. 3D printed benznidazole tablets based on an interpolyelectrolyte complex by melting solidification printing process (MESO-PP): an innovative strategy for personalized treatment of Chagas disease. Int J Pharm. 2024;662. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124476","DOI":"10.1016\/j.ijpharm.2024.124476"},{"issue":"11","key":"1989_CR70","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.xphs.2018.06.027","volume":"107","author":"A Simonazzi","year":"2018","unstructured":"Simonazzi A, Davies C, Cid AG, et al. Preparation and characterization of poloxamer 407 solid dispersions as an alternative strategy to improve benznidazole bioperformance. J Phar Sci. 2018;107(11):2829\u201336. https:\/\/doi.org\/10.1016\/j.xphs.2018.06.027","journal-title":"J Phar Sci"},{"key":"1989_CR71","doi-asserted-by":"publisher","unstructured":"Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23(3):534\u201347. Available from: https:\/\/doi.org\/10.1016\/j.drudis.2018.01.016","DOI":"10.1016\/j.drudis.2018.01.016"},{"key":"1989_CR72","doi-asserted-by":"publisher","unstructured":"Rolon M, Hanna E, Vega C, Coronel C, Dea-Ayuela MA, Serrano DR, et al. Solid nanomedicines of Nifurtimox and benznidazole for the oral treatment of Chagas disease. Pharmaceutics. 2022;141822. https:\/\/doi.org\/10.3390\/pharmaceutics14091822","DOI":"10.3390\/pharmaceutics14091822"},{"key":"1989_CR73","unstructured":"Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry. 2018. Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"1989_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discovery. 2004;3:785\u201393.","journal-title":"Nat Rev Drug Discovery"},{"key":"1989_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","volume":"156","author":"J Bermudez","year":"2016","unstructured":"Bermudez J, Davies C, Simonazzi A, Pablo Real J, Palma S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop. 2016;156:1\u201316. https:\/\/doi.org\/10.1016\/j.actatropica.2015.12.017","journal-title":"Acta Trop"},{"key":"1989_CR76","doi-asserted-by":"publisher","unstructured":"Veseli A, \u017dakelj S, Kristl A. A review of methods for solubility determination in biopharmaceutical drug characterization. Drug development and industrial pharmacy. Taylor and Francis Ltd.; 2019. pp. 1717\u201324. https:\/\/doi.org\/10.1080\/03639045.2019.1665062","DOI":"10.1080\/03639045.2019.1665062"},{"key":"1989_CR77","doi-asserted-by":"publisher","unstructured":"Lu Y, Qi J, Dong X, Zhao W, Wu W. The in vivo fate of nanocrystals. 2017;22(4):744\u201350. https:\/\/doi.org\/10.1016\/j.drudis.2017.01.003","DOI":"10.1016\/j.drudis.2017.01.003"},{"issue":"2","key":"1989_CR78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0378-5173(97)00311-6","volume":"160","author":"RH M\u00fcller","year":"1998","unstructured":"M\u00fcller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229\u201337. https:\/\/doi.org\/10.1016\/S0378-5173(97)00311-6","journal-title":"Int J Pharm"},{"issue":"6","key":"1989_CR79","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/gels11060410","volume":"11","author":"R Rhinow","year":"2025","unstructured":"Rhinow R, Franco MKKD, Vollrath MK, Kellermann G, Yokaichiya F. Poloxamer-Driven drug delivery system for Anti-Inflammatory drugs using Small-Angle neutron scattering approach. Gels. 2025;11(6):410. https:\/\/doi.org\/10.3390\/gels11060410","journal-title":"Gels"},{"issue":"2","key":"1989_CR80","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1248\/cpb.58.230","volume":"58","author":"MS Kim","year":"2010","unstructured":"Kim MS, Kim JS, Hwang SJ. Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives. Chem Pharm Bull (Tokyo). 2010;58(2):230\u20133.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"2","key":"1989_CR81","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pharma.2024.06.003","volume":"83","author":"R Chavhan","year":"2025","unstructured":"Chavhan R, Nanosuspensions. Enhancing drug bioavailability through Nanonization. Ann Pharm Fr. 2025;83(2):251\u201371. https:\/\/doi.org\/10.1016\/j.pharma.2024.06.003","journal-title":"Ann Pharm Fr"},{"key":"1989_CR82","unstructured":"Sruti J, Patra CN, Swain SK, Beg S, Palatasingh HR, Dinda SC et al. Improvement in Dissolution Rate of Cefuroxime Axetil by using Poloxamer 188 and Neusilin US2. Indian Journal of Pharmaceutical Sciences. Available from: www.ijpsonline.com"},{"issue":"4","key":"1989_CR83","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1208\/s12249-010-9517-6","volume":"11","author":"SG Castro","year":"2010","unstructured":"Castro SG, Bruni SS, Lanusse CE, Allemandi DA, Palma SD. Improved albendazole dissolution rate in pluronic 188 solid dispersions. AAPS PharmSciTech. 2010;11(4):1518\u201325. https:\/\/doi.org\/10.1208\/s12249-010-9517-6","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"1989_CR84","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1208\/s12248-009-9144-x","volume":"11","author":"A Dahan","year":"2009","unstructured":"Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world\u2019s top oral drugs. AAPS J. 2009;11(4):740\u20136. https:\/\/doi.org\/10.1208\/s12248-009-9144-x","journal-title":"AAPS J"},{"issue":"1","key":"1989_CR85","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","volume":"57","author":"Y Tsume","year":"2014","unstructured":"Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 2014;57(1):152\u201363. https:\/\/doi.org\/10.1016\/j.ejps.2014.01.009","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"1989_CR86","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1248\/bpb.b24-00566","volume":"47","author":"S Onoue","year":"2024","unstructured":"Onoue S. New drug delivery systems for stable oral absorption: Theory, Strategies, and applications. Biol Pharm Bull. 2024;47(11):1797\u2013803. https:\/\/doi.org\/10.1248\/bpb.b24-00566","journal-title":"Biol Pharm Bull"},{"key":"1989_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40005-013-0051-x","volume":"43","author":"S Ranjita","year":"2013","unstructured":"Ranjita S, Nanosuspensions. A new approach for organ and cellular targeting in infectious diseases. J Pharm Invest Kluwer Acad Publishers. 2013;43:1\u201326. https:\/\/doi.org\/10.1007\/s40005-013-0051-x","journal-title":"J Pharm Invest Kluwer Acad Publishers"},{"key":"1989_CR88","doi-asserted-by":"publisher","first-page":"102972","DOI":"10.1016\/j.eclinm.2024.102972","volume":"79","author":"A Rassi","year":"2025","unstructured":"Rassi A, Grimshaw A, Sarwal A, Sah R, Shah S, Agudelo Higuita NI, et al. Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. Syst Rev meta-analysis. 2025;79:102972. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102972","journal-title":"Syst Rev meta-analysis"},{"key":"1989_CR89","unstructured":"International Organization for Standardization. iso 10993 Biological evaluation of medical devices \u2014 Part 12: Sample preparation and reference materials. Iso 10993-12. 2004;3(4):1\u201320. Available from: http:\/\/down.40777.cn\/stardard\/11\/ISO 10993.12\u20132004 Biological evaluation of medical devices.pdf."},{"issue":"5","key":"1989_CR90","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s13346-023-01463-z","volume":"15","author":"JP Real","year":"2023","unstructured":"Real JP, Real DA, Lopez-Vidal L, Barrientos BA, Bola\u00f1os K, Tinti MG, et al. 3D-printed gastroretentive tablets loaded with niclosamide nanocrystals by the melting solidification printing process (MESO-PP). Pharmaceutics. 2023;15(5):1387. https:\/\/doi.org\/10.1007\/s13346-023-01463-z","journal-title":"Pharmaceutics"},{"key":"1989_CR91","doi-asserted-by":"publisher","first-page":"102695","DOI":"10.1016\/j.apmt.2025.102695","volume":"44","author":"L Lopez-Vidal","year":"2025","unstructured":"Lopez-Vidal L, Juskaite K, Fandino O, et al. 3D-printed acyclovir nanocrystals: an advanced approach to herpes simplex treatment. Appl Mater Today. 2025;44:102695. https:\/\/doi.org\/10.1016\/j.apmt.2025.102695","journal-title":"Appl Mater Today"},{"key":"1989_CR92","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0020-7519(01)00153-9","volume":"31","author":"KM Tyler","year":"2001","unstructured":"Tyler KM, Engman DM. The life cycle of trypanosoma Cruzi revisited. Int J Parasitol. 2001;31:472\u201381.","journal-title":"Int J Parasitol"},{"issue":"4","key":"1989_CR93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1358\/dot.2021.57.4.3251712","volume":"57","author":"R Thakare","year":"2021","unstructured":"Thakare R, Dasgupta A, Chopra S. Update on Nifurtimox for treatment of Chagas disease. Drugs Today. 2021;57(4):251\u201363. https:\/\/doi.org\/10.1358\/dot.2021.57.4.3251712","journal-title":"Drugs Today"},{"issue":"9","key":"1989_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.145523","volume":"6","author":"X Li","year":"2021","unstructured":"Li X, Yi S, Scariot DB, Martinez SJ, Falk BA, Olson CL, et al. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of trypanosoma Cruzi infection. JCI Insight. 2021;6(9):1\u201312. https:\/\/doi.org\/10.1172\/jci.insight.145523","journal-title":"JCI Insight"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01989-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:42:50Z","timestamp":1779108170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01989-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01989-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}